

# Suanna Steeby Bruinooge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7150656/publications.pdf>

Version: 2024-02-01

79

papers

3,951

citations

186265

28

h-index

123424

61

g-index

79

all docs

79

docs citations

79

times ranked

6547

citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018, 36, 1631-1641.   | 1.6 | 668       |
| 2  | Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 3826-3833.  | 1.6 | 343       |
| 3  | Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2017, 35, 3737-3744.  | 1.6 | 331       |
| 4  | Projected Supply of and Demand for Oncologists and Radiation Oncologists Through 2025: An Aging, Better-Insured Population Will Result in Shortage. <i>Journal of Oncology Practice</i> , 2014, 10, 39-45.  | 2.5 | 194       |
| 5  | Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. <i>Journal of Clinical Oncology</i> , 2015, 33, 3177-3185.  | 1.6 | 187       |
| 6  | Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. <i>JCO Oncology Practice</i> , 2020, 16, 417-421.  | 2.9 | 158       |
| 7  | Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology and Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 3753-3759. | 1.6 | 130       |
| 8  | Reviewing Cancer Care Team Effectiveness. <i>Journal of Oncology Practice</i> , 2015, 11, 239-246.  | 2.5 | 129       |
| 9  | The National Cancer Institute and American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and Recommendations. <i>Journal of Oncology Practice</i> , 2013, 9, 267-276.  | 2.5 | 121       |
| 10 | Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 1242-1253.   | 2.5 | 120       |
| 11 | The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. <i>Journal of Oncology Practice</i> , 2018, 14, e412-e420.   | 2.5 | 114       |
| 12 | Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.  | 3.0 | 98        |
| 13 | Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2443-2451.   | 1.6 | 97        |
| 14 | Modernizing Eligibility Criteria for Molecularly Driven Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2815-2820.  | 1.6 | 80        |
| 15 | Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 719-728.  | 0.8 | 78        |
| 16 | Teams and Teamwork During a Cancer Diagnosis: Interdependency Within and Between Teams. <i>Journal of Oncology Practice</i> , 2015, 11, 231-238.  | 2.5 | 72        |
| 17 | Enhancing the American Society of Clinical Oncology Workforce Information System With Geographic Distribution of Oncologists and Comparison of Data Sources for the Number of Practicing Oncologists. <i>Journal of Oncology Practice</i> , 2014, 10, 32-38.                                | 2.5 | 70        |
| 18 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171.   | 1.6 | 68        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169.   | 1.6 | 65        |
| 20 | Palbociclib in Patients With Non-“Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2020, 4, 757-766.  | 3.0 | 52        |
| 21 | Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. Journal of Clinical Oncology, 2015, 33, 3961-3967.  | 1.6 | 50        |
| 22 | Tracking the Workforce: The American Society of Clinical Oncology Workforce Information System. Journal of Oncology Practice, 2013, 9, 3-8.   | 2.5 | 48        |
| 23 | Understanding the Role of Advanced Practice Providers in Oncology in the United States. Journal of Oncology Practice, 2018, 14, e518-e532.  | 2.5 | 48        |
| 24 | Access to Chemotherapy Services by Availability of Local and Visiting Oncologists. Journal of Oncology Practice, 2014, 10, 26-31.   | 2.5 | 47        |
| 25 | Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-“Friends of Cancer Research Joint Research Statement. Clinical Cancer Research, 2021, 27, 2394-2399.   | 7.0 | 47        |
| 26 | Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2019, 3, 1-8.  | 3.0 | 46        |
| 27 | The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center. Clinical Cancer Research, 2010, 16, 5997-6003.  | 7.0 | 38        |
| 28 | Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research, 2021, 27, 2424-2429.   | 7.0 | 35        |
| 29 | Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. Journal of Clinical Oncology, 2016, 34, 3796-3802. | 1.6 | 29        |
| 30 | Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology, 2019, 37, 1014-1014.                           | 1.6 | 29        |
| 31 | Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-“Small Cell Lung Cancer: Real-World Analysis of Select ASCO-“Friends” Recommendations. Clinical Cancer Research, 2021, 27, 2430-2434.  | 7.0 | 28        |
| 32 | Defining comprehensive biomarker-related testing and treatment practices for advanced non-“small” cell lung cancer: Results of a survey of U.S. oncologists. Cancer Medicine, 2022, 11, 530-538.  | 2.8 | 28        |
| 33 | National Cancer Institute-“American Society of Clinical Oncology Teams in Cancer Care Project. Journal of Oncology Practice, 2016, 12, 955-958.   | 2.5 | 27        |
| 34 | Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2018, 36, 2532-2532.     | 1.6 | 27        |
| 35 | Where Do Patients With Cancer in Iowa Receive Radiation Therapy?. Journal of Oncology Practice, 2014, 10, 20-25.  | 2.5 | 26        |
| 36 | Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750.  | 3.6 | 25        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.                               | 1.6 | 22        |
| 38 | Challenges to National Cancer Institute's Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. <i>Journal of Oncology Practice</i> , 2010, 6, 114-117.  | 2.5 | 19        |
| 39 | Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2022, 18, e426-e441.   | 2.9 | 16        |
| 40 | Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate. <i>Cancer</i> , 2017, 123, 2893-2900.  | 4.1 | 13        |
| 41 | Intentional Approach to Team-Based Oncology Care: Evidence-Based Teamwork to Improve Collaboration and Patient Engagement. <i>Journal of Oncology Practice</i> , 2015, 11, 247-248.   | 2.5 | 11        |
| 42 | Ethics in Oncology: Consulting for the Investment Industry. <i>Journal of Clinical Oncology</i> , 2007, 25, 444-446.  | 1.6 | 10        |
| 43 | Assessment of Risk Evaluation and Mitigation Strategies in Oncology: Summary of the Oncology Risk Evaluation and Mitigation Strategies Workshop. <i>Journal of Oncology Practice</i> , 2013, 9, e24-e39.  | 2.5 | 10        |
| 44 | Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA108-LBA108.   | 1.6 | 10        |
| 45 | The Impact of the Privacy Rule on Cancer Research: Variations in Attitudes and Application of Regulatory Standards. <i>Journal of Clinical Oncology</i> , 2009, 27, 4014-4020.  | 1.6 | 9         |
| 46 | Impact on Oncology Practices of Including Drug Costs in Bundled Payments. <i>Journal of Oncology Practice</i> , 2018, 14, e259-e268.  | 2.5 | 7         |
| 47 | Understanding the role of advanced practice providers in oncology in the United States. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2018, 31, 1-12.  | 0.3 | 7         |
| 48 | Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. <i>Journal of Oncology Practice</i> , 2019, 15, 575-583.  | 2.5 | 7         |
| 49 | Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. <i>JCO Oncology Practice</i> , 2021, 17, e336-e342.  | 2.9 | 7         |
| 50 | Challenges and opportunities to developing a frailty index using electronic health record data. <i>Journal of Geriatric Oncology</i> , 2021, 12, 851-854.   | 1.0 | 7         |
| 51 | Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9041-9041. | 1.6 | 7         |
| 52 | Understanding the Role of Advanced Practice Providers in Oncology in the United States. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 585-598.   | 0.4 | 7         |
| 53 | The Changing Face of Research in Community Practice. <i>Journal of Oncology Practice</i> , 2014, 10, 155-160.   | 2.5 | 4         |
| 54 | A New Look at the State of Cancer Care in America. <i>Journal of Oncology Practice</i> , 2018, 14, 397-399.   | 2.5 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors. <i>Journal of Oncology Practice</i> , 2019, 15, e1050-e1065.     | 2.5 | 3         |
| 56 | Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 480-487.                         | 1.6 | 3         |
| 57 | Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. <i>JCO Oncology Practice</i> , 2021, 17, 41-51.  | 2.9 | 3         |
| 58 | Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. <i>JCO Oncology Practice</i> , 2021, 17, e999-e1011.   | 2.9 | 3         |
| 59 | State of Cancer Care in America: Reflections on an Inaugural Year. <i>Journal of Oncology Practice</i> , 2019, 15, 163-165.   | 2.5 | 2         |
| 60 | Physician concern about delaying lung cancer treatment while awaiting biomarker testing: Results of a survey of U.S. oncologists.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9067-9067.                 | 1.6 | 2         |
| 61 | Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6530-6530.          | 1.6 | 2         |
| 62 | Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6531-6531.   | 1.6 | 1         |
| 63 | Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19311-e19311.              | 1.6 | 1         |
| 64 | NGS testing use and results: A survey of U.S. oncologists.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19145-e19145.  | 1.6 | 1         |
| 65 | Assessing feasibility and utility of an implicit bias training program for addressing disparities in cancer clinical trial participation.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18599-e18599.     | 1.6 | 1         |
| 66 | Reply to H.G. Muntz et al. <i>Journal of Oncology Practice</i> , 2015, 11, 428-428.   | 2.5 | 0         |
| 67 | Reply to N. Lowy et al and to J. Dhanda et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1708-1709.   | 1.6 | 0         |
| 68 | ASCO's Selection of Oncologist Workforce Data Source. <i>JCO Oncology Practice</i> , 2021, 17, 295-296.   | 2.9 | 0         |
| 69 | Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6509-6509.  | 1.6 | 0         |
| 70 | Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17561-e17561. | 1.6 | 0         |
| 71 | Predictors of insurance denials for cancer clinical trial participation after ACA mandate.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14047-e14047.  | 1.6 | 0         |
| 72 | Hypertension and use of bevacizumab among patients treated in community settings.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18279-e18279.   | 1.6 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Annual trends in opioid prescribing for patients (Pts) with metastatic non-small cell lung cancer (mNSCLC): CancerlinQ data analysis, 2010 to 2017.. Journal of Clinical Oncology, 2020, 38, 2076-2076.                          | 1.6 | 0         |
| 74 | Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. Journal of Clinical Oncology, 2020, 38, e19046-e19046.                                   | 1.6 | 0         |
| 75 | Associations between biomarker testing and characteristics of patients with metastatic non-small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data.. Journal of Clinical Oncology, 2022, 40, 9127-9127. | 1.6 | 0         |
| 76 | Presentation, management, and outcome of COVID-19 among patients with cancer in the Middle East and North Africa (MENA) region.. Journal of Clinical Oncology, 2022, 40, e18797-e18797.  | 1.6 | 0         |
| 77 | COVID-19 vaccine uptake in patients with cancer and Sars-Cov-2 infection in 2020: Results from the ASCO registry.. Journal of Clinical Oncology, 2022, 40, e18713-e18713.  | 1.6 | 0         |
| 78 | Oncologists'™ perspectives on individualizing dose selection for patients with metastatic cancer.. Journal of Clinical Oncology, 2022, 40, 1531-1531.  | 1.6 | 0         |
| 79 | Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.. Journal of Clinical Oncology, 2022, 40, e18807-e18807.  | 1.6 | 0         |